Journal of Investigative Dermatology Symposium Proceedings Impact Factor & Information

Publisher: Society for Investigative Dermatology; European Society for Dermatological Research, Nature Publishing Group

Journal description

Current impact factor: 3.73

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2011 Impact Factor 3.733
2010 Impact Factor 1.19
2009 Impact Factor 1.435
2008 Impact Factor 1.576
2007 Impact Factor 1.576
2006 Impact Factor 2.191
2005 Impact Factor 2.392
2004 Impact Factor 0.308
2003 Impact Factor 0.867
2002 Impact Factor 0.613
2001 Impact Factor 0.962

Impact factor over time

Impact factor

Additional details

5-year impact 2.48
Cited half-life 7.80
Immediacy index 0.88
Eigenfactor 0.00
Article influence 0.73
Other titles Journal of investigative dermatology., The journal of investigative dermatology. Symposium proceedings, JID symposium proceedings, Symposium proceedings
ISSN 1529-1774
OCLC 43647738
Material type Conference publication, Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Nature Publishing Group

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 6 months embargo
  • Conditions
    • Authors retain copyright
    • Author's pre-print on arXiv or bioRXiv
    • Author's post-print on author's personal website, institutional repository, PubMed Central or funding body's archive
    • Published source must be acknowledged
    • Must link to publisher version with DOI
    • Publisher's version/PDF cannot be used
  • Classification
    ​ yellow

Publications in this journal

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Founded in 1981, the National Alopecia Areata Foundation (NAAF) is dedicated to research to find a cure or acceptable treatment for alopecia areata (AA), to develop support for people affected by the disease, and to educate the public about it. NAAF has developed into an international organization advancing patient interests in a number of ways. Beginning in 2008, NAAF organized a series of research summits that focused AA research investments into genetic, molecular, and immunological investigations as well as laying the groundwork for clinical trials and support for regulatory evaluation of prospectively available treatments. This multifaceted initiative is called the Alopecia Areata Treatment Development Program (TDP). It is representative of initiatives among voluntary patient advocacy organizations to partner with academic, clinical, government, and biotechnology interests to accelerate the development and approval of treatments for understudied diseases. The article describes key steps in the development of TDP, its progress, and future direction.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S46-7. DOI:10.1038/jidsymp.2013.16
  • Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S10-2. DOI:10.1038/jidsymp.2013.3
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although the association between alopecia areata (AA), psoriasis, and other autoimmune diseases has been well reported in the literature, an association with metabolic syndrome has not been reported. We present two young women with the combination of severe psoriasis, androgen excess, metabolic syndrome, thyroiditis, and AA. Both women ultimately progressed to treatment-resistant alopecia universalis. This constellation of autoimmunity and metabolic syndrome presents a therapeutic challenge while highlighting the need for full laboratory assessment of AA patients. Careful selection of biological treatment regimens may offer therapeutic benefit for both their psoriasis and AA while giving us experience with the newer biologics in AA.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S56-7. DOI:10.1038/jidsymp.2013.22
  • [Show abstract] [Hide abstract]
    ABSTRACT: The onset of alopecia areata creates a roller coaster of emotions. Like the disease, a patient's emotions are unpredictable. The lack of control over one's body is both frightening and intimidating. Alopecia areata not only impacts an individual but it also has a halo effect, impacting family and friends, thereby increasing the number of people affected by the disease.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S41. DOI:10.1038/jidsymp.2013.13
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alopecia areata is the only condition that can cause complete hair loss in 3 months without symptoms or signs.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S65-6. DOI:10.1038/jidsymp.2013.27
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although alopecia areata (AA) is not life threatening, it may lead to severe psychological disturbances, reducing the quality of life in all ages. Thus, a new animal model is needed for shedding more light onto the pathogenesis of this cell-mediated, organ-specific autoimmune disease to identify more effective therapeutic strategies. Recently, we succeeded in developing a new humanized mouse model of AA, which includes transplantation of healthy human scalp skin obtained from normal volunteers on to severe-combined immunodeficient mice. This is followed by intradermal injection of either autologous or allogeneic peripheral blood mononuclear cells, which had been cultured with high dose of IL-2 and enriched for natural killer group 2D-positive (NKG2D+) and CD56+ cells. This protocol leads to rapid and predictable development of focal hair loss, with all the characteristic clinical, histological, and immunohistochemical features of AA. This humanized mouse AA model underscores the functional importance of NKG2D+ and CD56+ cells in AA pathogenesis and promises to be instrumental for identifying novel AA treatment strategies.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S37-8. DOI:10.1038/jidsymp.2013.11
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alopecia areata, alopecia totalis, and alopecia universalis likely represent a constellation of related diseases with similar, yet distinct heritability markers. There is currently no known curative therapy that works universally for all patients. Pharmacogenomic research enables the pharmaceutical industry to understand variability of patient responses to drugs during clinical drug development and during post-marketing surveillance. Understanding the genetic basis for patient response/non-response can enable the development of individualized therapies for those patients with an inherited basis for altered response to drug therapy. There are multiple examples of drugs that now contain a recommendation for genetic testing before dosing in their drug labels, directing clinicians to obtain genetic information for each individual patient in order to help direct drug therapy.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S39-40. DOI:10.1038/jidsymp.2013.12
  • [Show abstract] [Hide abstract]
    ABSTRACT: Peg-interferon alpha-2a and 2b and ribavirin have become the mainstays of chronic hepatitis C treatment. Although various cutaneous side effects have been reported, alopecia areata in its various forms have rare reports and has not been well categorized. Here we present a case of alopecia universalis occurring shortly after treatment for chronic hepatitis C, and we discuss some of the implications this has in understanding the pathophysiology of alopecia areata.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S59-60. DOI:10.1038/jidsymp.2013.24
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Reported is a patient with severe alopecia areata, multiple autoimmune diseases (chronic lymphocytic thyroidis, primary ovarian failure), and Down syndrome. She had a poor response to topical treatment with glucocorticoids and minoxidil, but showed some improvement with glucocorticoid injections. At the time of evaluation, she had hair loss on 85-90% of her scalp. She was treated initially with oral prednisone 50 mg per day for 2 weeks, followed by a 3-month course of prednisone 10 mg per day and cyclosporine 125 mg (4 mg kg(-1)) two times per day. She responded well with excellent regrowth of hair on the scalp, and prednisone was tapered and ultimately discontinued. Importantly, her parents noted marked improvement in sense of well-being. Several months after discontinuing treatment, she developed hyperpigmentation on the trunk consistent with confluent and reticulated papillomatosis; she has several known risk factors for this disorder, but it is not clear if this is related to her previous treatment.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S58. DOI:10.1038/jidsymp.2013.23
  • [Show abstract] [Hide abstract]
    ABSTRACT: Previous genetic epidemiological studies of psoriasis and alopecia areata demonstrated strong heritability in first-degree relatives and in twins. In recent years, these two conditions have emerged as two skin diseases that are starting to yield their secrets through genome-wide association studies. Both diseases manifest prominent human leukocyte antigen (HLA) associations, psoriasis primarily with major histocompatibility complex (MHC) Class 1, specifically HLA-Cw6, and alopecia areata primarily with MHC Class II. Despite these differences in HLA associations, both diseases have in common a prominent role for CD8+ lymphocytes. The purpose of this brief review is to present the recent developments in the genetics of psoriasis.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S34-6. DOI:10.1038/jidsymp.2013.10
  • Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S5-9. DOI:10.1038/jidsymp.2013.2
  • Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S53. DOI:10.1038/jidsymp.2013.20
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A young female child aged 7 years presented initially with chronic alopecia areata, which over 2 years progressed to alopecia areata universalis.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S54-5. DOI:10.1038/jidsymp.2013.21
  • [Show abstract] [Hide abstract]
    ABSTRACT: IL-15 has a pivotal role in life and death of natural killer (NK) and CD8 memory T cells. IL-15 signals through a heterotrimeric receptor involving the common gamma chain (γc) shared with IL-2, IL-4, IL-7, IL-9, and IL-21, IL-2/IL-15 receptor β (IL-15Rβ) shared with IL-2 and a private IL-15Rα subunit. IFN- or CD40 ligand-stimulated dendritic cells coordinately express IL-15 and IL-15Rα. Cell surface IL-15Rα presents IL-15 in trans to cells that express IL-2/IL-15Rβ and γc. IL-15 is being used to treat patients with metastatic malignancy. However, IL-15 is an inflammatory cytokine involved in immunological memory including that to self, thereby playing a role in autoimmune diseases. These insights provide the scientific basis for clinical strategies directed toward diminishing IL-15 action. Dysregulated IL-15 expression was demonstrated in patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, celiac disease, and alopecia areata. The monoclonal antibody Hu-Mik-β-1 targets the cytokine receptor subunit IL-2/IL-15Rβ (CD122), blocks IL-15 transpresentation, and is being used in clinical trials in patients with autoimmune diseases. In parallel, clinical trials have been initiated involving the Jak2/3 (Janus kinase-2/3) inhibitor tofacitinib and Jak1/2 inhibitor ruxolitinib to block IL-15 signaling.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S28-30. DOI:10.1038/jidsymp.2013.8
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alopecia areata is a complex genetic, immune-mediated disease that targets anagen hair follicles. The disease affects children and adults and is characterized by round or oval patches of hair loss, loss of all scalp hair (alopecia totalis), body hair (alopecia universalis), or ophiasis pattern hair loss. Patients may also present with patchy loss in multiple hair-bearing areas. Commonly associated diseases include asthma, allergic rhinitis, atopic dermatitis, thyroid disease, and automimmune diseases, such as thyroiditis and vitiligo. Nail abnormalities may precede, follow, or occur concurrently with hair loss activity. Alopecia areata has no known age, race, or ethnic preponderance and in contrast to other autoimmune diseases such as thyroiditis or lupus, the hair follicle does not usually sustain permanent injury and maintains its potential to regrow hair. It is estimated that alopecia areata affects between six and seven million individuals in the United States. Genes, the immune and nervous systems have all been implicated in the pathogenesis of alopecia areata. Although many treatments are available, there is still no cure. Bolstered by new scientific and translational opportunities from recently published genome-wide association studies, an ambitious treatment development program has recently been initiated by the National Alopecia Areata Foundation.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S13-5. DOI:10.1038/jidsymp.2013.4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alopecia areata (AA) is a nonscarring and recurrent disease characterized by hair loss that may significantly affect patient health-related quality of life (HRQoL). Given the lack of reliable and accurate reporting of HRQoL status in patients with AA, we analyzed data from 532 AA patients from the National Alopecia Areata Registry whose registry record included HRQoL assessments using three validated instruments: Skindex-16, brief version of the Fear of Negative Evaluation Scale, and Dermatology Life Quality Index. The mean HRQoL scores were compared with previously reported HRQoL levels from healthy controls and patients with other skin diseases. Two-step cluster analysis of Skindex-16 scales divided patients into two groups: 481 (57%) with good HRQoL and 361 (43%) with poor HRQoL. Multivariate logistic regression modeling revealed a set of risk factors for poor HRQoL: age <50 years (odds ratio (OR) 3.99, 95% confidence interval (CI) 1.66-9.58), female gender (OR 2.74, 95% CI 1.73-4.34), hair loss 25-99% (OR 2.47, 95% CI 1.12-5.45), family stress (OR 1.8, 95% CI 1.13-2.86), and job change (OR 2.01, 95% CI 1.02-3.94). The current analysis provides an overview of the HRQoL status of AA patients and may guide patient care in the future.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S49-50. DOI:10.1038/jidsymp.2013.18
  • [Show abstract] [Hide abstract]
    ABSTRACT: The differential diagnosis of a strongly positive and painless hair pull test includes alopecia areata and loose anagen syndrome. A hair mount examined with low power light microscopy easily clarifies the diagnosis.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S63-4. DOI:10.1038/jidsymp.2013.26
  • [Show abstract] [Hide abstract]
    ABSTRACT: Within the area of alopecia areata research, there is an obvious need for well-designed clinical trials of therapeutic agents. The National Alopecia Areata Foundation (NAAF) has created an initiative for the development of a unified protocol with guidelines for clinical studies. The NAAF universal protocol represents a joint effort of clinicians and investigators with experience in treating alopecia areata. This protocol will serve as a tremendous resource to facilitate future clinical studies.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S48. DOI:10.1038/jidsymp.2013.17
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alopecia areata (AA) is an autoimmune condition characterized by T cell-mediated attack of the hair follicle. The inciting antigenic stimulus is unknown. A dense perbulbar lymphocytic infiltrate and reproducible immunologic abnormalities are hallmark features of the condition. The cellular infiltrate primarily consists of activated T lymphocytes and antigen-presenting Langerhans cells. The xenon chloride excimer laser emits its total energy at the wavelength of 308 nm and therefore is regarded as a "super-narrowband" UVB light source. Excimer laser treatment is highly effective in psoriasis, another T cell-mediated disorder that shares many immunologic features with AA. The excimer laser is superior in inducing T cell apoptosis in vitro compared with narrowband UVB, with paralleled improved clinical efficacy. The excimer laser has been used successfully in patients with AA. In this context, evaluation of the potential benefit of 308-nm excimer laser therapy in the treatment of AA is clinically warranted. Herein, the use of a common treatment protocol with a specifically designed module to study the outcome of excimer laser treatment on moderate-to-severe scalp AA in adults is described.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S77-9. DOI:10.1038/jidsymp.2013.31
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Few dermatologic conditions carry as much anxiety and emotional distress as hair loss resulting from a disease condition such as alopecia areata or as a result of cytotoxic drug treatment, e.g., after chemotherapy. Bimatoprost 0.03% solution is a Food and Drug Administration-approved prescription product indicated for the treatment of eyelash hypotrichosis. The product was investigated in a double-masked, randomized, and placebo-controlled study in patients who had significant eyelash loss or hypotrichosis as a result of chemotherapy. Once-daily treatment with bimatoprost ophthalmic solution 0.03% to the upper eyelid margin restored eyelash growth and prominence more quickly than the slower, natural course of recovery observed in the vehicle control subjects. The eyelash prominence measured using a validated Global Eyelash Assessment (GEA) scale demonstrated a statistically significant increase over placebo following 6 months of treatment. Efficacy was also demonstrated using a validated objective digital image analysis methodology to show significant increase in eyelash length, thickness/fullness, and darkness in these patients. Bimatoprost was found to be well tolerated over the 1-year treatment period.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S73-6. DOI:10.1038/jidsymp.2013.30